Auf dieser Seite
WHWK Whitehawk Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$3,70
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$1,8752-Wochen-Tief
$5,5052-Wochen-Hoch
Marktkapitalisierung (MRQ)
$211M
P/E (TTM)
-1.9
EPS (TTM)
$-1.92
Umsatz (TTM)
$0
Ihre Abzeichen
52W-Spanne
$2–$5
Analystenbewertung
BUY
Kursziel
$8
P/E
-1.9
ROE
-45.0%
Nettogewinnmarge
-288.3%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
WHWK Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$3.70
Marktkapitalisierung (MRQ)
$211M
P/E (TTM)
-1.9
EPS (TTM)
$-1.92
Umsatz (TTM)
$0
ROE (TTM)
-45.0%
52W-Spanne
$2–$5
WHWK Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 27. August 2021 | 1-for-15 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$7M2018-12-31 → 2025-12-31
EPS$-0.332021-12-31 → 2025-12-31
Freier Cashflow$-98M2018-12-31 → 2025-12-31
Nettogewinnmarge-288.3%2018-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | WHWK | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -1.95-Jahres-Durchschnitt ≈-3.2 | ≈-3.2 | · | · | |
| P/S | 24.45-Jahres-Durchschnitt ≈15.5 | ≈15.5 | 16.1 | Fairer Wert | |
| K/B (MRQ) | 1.25-Jahres-Durchschnitt ≈1.7 | ≈1.7 | 2.5 | Unterbewertet | |
| Kurs / FCF (TTM) | -3.05-Jahres-Durchschnitt ≈-6.4 | ≈-6.4 | · | · | |
| Kurs / Cashflow (TTM) | -3.05-Jahres-Durchschnitt ≈-6.4 | ≈-6.4 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 1.35-Jahres-Durchschnitt ≈1.7 | ≈1.7 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | WHWK | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Operating Margin (Betriebsgewinnmarge) | -1601.1%5-Jahres-Durchschnitt ≈-2499.6% | ≈-2499.6% | -1113.3% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -1600.0%5-Jahres-Durchschnitt ≈-2497.0% | ≈-2497.0% | -1113.3% | Schwach | |
| Pretax Margin (Vorgewinnmarge) | -288.3%5-Jahres-Durchschnitt ≈-2206.1% | ≈-2206.1% | -688.6% | Spitzenklasse | |
| Net Profit Margin (Nettogewinnmarge) | -288.3%5-Jahres-Durchschnitt ≈-2206.1% | ≈-2206.1% | -1287.2% | Spitzenklasse | |
| ROA (TTM) | -42.6%5-Jahres-Durchschnitt ≈-56.6% | ≈-56.6% | -27.9% | Spitzenklasse | |
| ROE (TTM) | -45.0%5-Jahres-Durchschnitt ≈-58.2% | ≈-58.2% | -27.2% | Spitzenklasse | |
| ROIC | -83.9%5-Jahres-Durchschnitt ≈-80.4% | ≈-80.4% | -67.7% | Unterdurchschnittlich |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | WHWK | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 17.45-Jahres-Durchschnitt ≈7.6 | ≈7.6 | 7.9 | Starke Liquidität | |
| Quick Ratio | 10.05-Jahres-Durchschnitt ≈7.3 | ≈7.3 | 6.5 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | WHWK | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | -72.5%5-Jahres-Durchschnitt ≈0.59% | ≈0.59% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -22.3%5-Jahres-Durchschnitt ≈7.0% | ≈7.0% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | -12.6% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | WHWK | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.15-Jahres-Durchschnitt ≈0.1 | ≈0.1 | 0.1 | Im Einklang | |
| Inventory Turnover (Lagerumschlag) | 0.35-Jahres-Durchschnitt ≈0.7 | ≈0.7 | · | · | |
| Receivables Turnover (Forderungsumschlag) | 2.45-Jahres-Durchschnitt ≈7.5 | ≈7.5 | 2.6 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$223.3K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-130.5%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 5, 2026 | $-0.20 | $-0.30 | 33.7% |
| 31. März 2026 | $-0.32 | $-0.36 | 12.1% | |
| 31. Dezember 2025 | $-0.34 | $-0.16 | -116.4% | |
| 30. September 2025 | $-0.26 | $0.07 | -482.4% | |
| 30. Juni 2025 | $-0.76 | $0.50 | -251.0% | |
| 31. März 2025 | $-0.37 | $-0.47 | 21.1% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7M | $26M | $24M | $15M | $14M | $14M | $0 | $20M | |
| Cost of Revenue | $760.0K | $3M | $3M | $1M | $0 | · | · | · | |
| R&D Expense | $91M | $51M | $49M | $33M | $20M | $15M | $13M | $18M | |
| SG&A Expense | $30M | $37M | $45M | $40M | $19M | $2M | $10M | $13M | |
| Operating Expenses | $122M | $93M | $96M | $78M | $112M | $17M | $24M | $31M | |
| Operating Income | $-114M | $-67M | $-72M | $-63M | $-111M | $-3M | $-24M | $-11M | |
| Interest Expense | · | · | $231.0K | $230.0K | $665.0K | $815.0K | · | · | |
| Interest Income | $6M | $4M | $6M | $2M | $13.0K | $41.0K | · | · | |
| Other Non-op | $94M | $4M | $6M | $2M | $1M | $-927.0K | $1M | $784.6K | |
| Pretax Income | $-21M | $-64M | $-66M | $-61M | $-110M | $-3M | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | $2.0K | $2.0K | · | · | |
| Net Income | $-21M | $-64M | $-66M | $-61M | $-110M | $-3M | $-23M | $-10M | |
| EPS (Basic) | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 | · | · | · | |
| EPS (Diluted) | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 | · | · | · | |
| Shares (Basic) | 61,886,765 | 27,029,942 | 26,917,967 | 22,511,237 | 8,923,369 | · | · | · | |
| Shares (Diluted) | 61,886,765 | 27,029,942 | 26,917,967 | 22,511,237 | 8,923,369 | · | · | · | |
| EBITDA | $-114M | $-67M | $-72M | $-63M | $-111M | $-6M | $-24M | $-11M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $38M | $29M | $63M | $39M | $149M | $4M | $39M | $63M | |
| Short-term Investments | $108M | $19M | $46M | $134M | $0 | · | · | · | |
| Receivables | $0 | $6M | $5M | $2M | $0 | $14M | · | · | |
| Inventory | $0 | $5M | $6M | $2M | $0 | · | · | · | |
| Prepaid Expense | $3M | $3M | $4M | $4M | $2M | $81.0K | $311.2K | $754.4K | |
| Other Current Assets | · | · | · | · | · | $2M | $734.8K | $615.7K | |
| Current Assets | $149M | $61M | $125M | $180M | $151M | $19M | $40M | $64M | |
| PP&E (Net) | $3.0K | $7M | $5M | $508.0K | $57.0K | $21.0K | $164.2K | $98.4K | |
| PP&E (Gross) | $377.0K | $7M | $5M | $609.0K | $87.0K | $512.1K | $493.0K | $409.6K | |
| Accum. Depreciation | $374.0K | $463.0K | $270.0K | $101.0K | $30.0K | $390.3K | $328.9K | $311.1K | |
| Intangibles | · | · | · | $0 | $4M | · | · | · | |
| Other Non-current Assets | $2M | $1M | $2M | $2M | $2M | · | · | · | |
| Total Assets | $151M | $70M | $132M | $184M | $158M | $19M | $40M | $64M | |
| Accounts Payable | $917.0K | $2M | $6M | $4M | $6M | $2M | $439.8K | $595.7K | |
| Accrued Liabilities | $14M | $15M | $14M | $15M | $9M | $4M | · | · | |
| Current Liabilities | $15M | $17M | $26M | $19M | $15M | $30M | $3M | $5M | |
| Capital Leases | $0 | $565.0K | $833.0K | $1M | $474.0K | · | $67.4K | · | |
| Other Non-current Liabilities | $0 | $202.0K | $0 | · | $0 | $97.0K | · | · | |
| Total Liabilities | $15M | $18M | $27M | $26M | $22M | $31M | $3M | $5M | |
| Common Stock | $4.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $4.1K | $4.1K | |
| Retained Earnings | $-353M | $-333M | $-269M | $-203M | $-143M | $-33M | $-142M | $-119M | |
| AOCI | $120.0K | $16.0K | $27.0K | $-115.0K | $0 | · | · | · | |
| Stockholders' Equity | $136M | $52M | $105M | $158M | $136M | $-12M | $-9M | $59M | |
| Liabilities + Equity | $151M | $70M | $132M | $184M | $158M | $19M | $40M | $64M | |
| Shares Outstanding | 47,145,719 | 24,681,000 | 24,554,000 | 24,435,000 | 20,895,000 | 2,542,358 | 40,588,004 | 40,588,004 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $79.0K | $193.0K | $169.0K | $159.0K | $105.0K | $9.0K | · | · | |
| Stock-based Comp | $10M | $11M | $12M | $10M | $2M | $139.0K | $1M | $3M | |
| Deferred Tax | · | · | · | · | $0 | $0 | $0 | $0 | |
| Amort. of Intangibles | · | · | $0 | $87.0K | $95.0K | $0 | · | · | |
| Restructuring | $0 | $3M | $0 | · | · | · | · | · | |
| Other Non-cash | $-87M | $-7M | $-6M | $1M | $85M | · | · | · | |
| Operating Cash Flow | $-97M | $-60M | $-60M | $-50M | $-22M | $-13M | $-24M | $-6M | |
| CapEx | $552.0K | $2M | $4M | $444.0K | $46.0K | $19.0K | $237.0K | $37.9K | |
| Investing Cash Flow | $12M | $25M | $83M | $-133M | $25M | $-19.0K | $-237.0K | $-37.9K | |
| Stock Issued | · | · | · | $0 | $155M | $10M | · | $52M | |
| Net Stock Activity | · | · | · | $0 | $155M | $10M | · | $52M | |
| Dividends Paid | · | · | · | $0 | $4M | · | · | · | |
| Financing Cash Flow | $94M | $130.0K | $326.0K | $73M | $142M | $1M | · | $48M | |
| Net Change in Cash | $9M | $-34M | $24M | $-110M | $145M | $-12M | $-24M | $42M | |
| Free Cash Flow | $-98M | $-61M | $-64M | $-50M | $-22M | $-5M | $-24M | $-6M | |
| Levered FCF | · | · | $-64M | $-50M | $-23M | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1601.1% | -259.6% | -295.4% | -411.9% | -9930.1% | -42.4% | · | -55.5% | |
| Net Margin | -288.3% | -245.1% | -270.0% | -397.7% | -9829.5% | -28.8% | · | -51.6% | |
| Pretax Margin | -288.3% | -245.1% | -270.0% | -397.7% | -9829.3% | · | · | · | |
| EBITDA Margin | -1600.0% | -258.9% | -294.7% | -410.9% | -9920.7% | -42.4% | · | -55.5% | |
| ROA | -18.6% | -62.8% | -41.5% | -35.4% | -124.6% | -10.2% | -44.7% | -24.4% | |
| ROE | -13.4% | -105.0% | -58.9% | -37.0% | -76.6% | -38.2% | -59.5% | -16.6% | |
| ROIC | -83.9% | -128.6% | -68.4% | -39.6% | -81.5% | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.3 | 3.6 | 4.7 | 9.6 | 9.9 | 24.0 | 11.9 | 11.7 | |
| Quick Ratio | 10.0 | 3.1 | 4.3 | 9.3 | 9.8 | 22.8 | 11.6 | 11.5 | |
| Interest Coverage | · | · | -311.4 | -272.5 | -167.2 | · | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.3 | 0.2 | 0.1 | 0.0 | 0.4 | · | 0.5 | |
| Inventory Turnover | 0.3 | 0.5 | 0.7 | 1.4 | · | · | · | · | |
| Receivables Turnover | 2.4 | 4.6 | 6.6 | 16.3 | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.89 | $2.13 | $4.28 | $6.48 | $6.53 | $0.91 | $0.90 | $1.45 | |
| Revenue / Share | $0.12 | $0.96 | $0.90 | $0.68 | · | · | · | · | |
| Cash Flow / Share | $-1.57 | $-2.20 | $-2.22 | $-2.21 | · | · | · | · | |
| Cash / Share | $0.80 | $1.16 | $2.56 | $1.60 | $7.13 | $0.90 | $0.95 | $1.54 | |
| EPS (TTM) | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -72.5% | 6.7% | 60.1% | 8.7% | 0.00% | · | · | · | |
| Revenue CAGR 3Y | -22.3% | 22.9% | 20.3% | · | · | · | · | · | |
| Revenue CAGR 5Y | -12.6% | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $7M | $26M | $24M | $15M | $14M | $14M | $0 | $20M | |
| Net Income TTM | $-21M | $-64M | $-66M | $-61M | $-110M | $-3M | $-23M | $-10M | |
| Market Cap | $114M | $78M | $50M | $314M | $505M | $695M | $380M | $1.03B | |
| P/E | -7.3 | -1.3 | -0.8 | -4.8 | -1.9 | · | · | · | |
| P/S | 16.0 | 3.0 | 2.0 | 20.6 | 36.0 | 49.6 | · | 51.3 | |
| P/B | 0.8 | 1.5 | 0.5 | 2.0 | 3.7 | 16.1 | 10.4 | 17.6 | |
| P / Tangible Book | 0.8 | 1.5 | 0.5 | 2.0 | 3.8 | · | · | · | |
| P / Cash Flow | -1.2 | -1.3 | -0.8 | -6.3 | -22.5 | -129.0 | -15.9 | -178.2 | |
| P / FCF | -1.2 | -1.3 | -0.8 | -6.3 | -22.5 | -128.5 | -15.8 | -177.0 | |
| Dividend Yield | · | · | · | 0.00% | 0.87% | · | · | · | |
| Earnings Yield | -13.6% | -74.8% | -120.8% | -21.0% | -51.4% | · | · | · | |
| Payout Ratio | · | · | · | 0.00% | -4.0% | · | · | · | |
| Annual Payout | · | · | · | $0 | $4M | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $7M | $7M | $7M | $6M | $5M | $6M | $6M | $6M | $6M | $5M | $4M | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $760.0K | $790.0K | $804.0K | $778.0K | $652.0K | $927.0K | $697.0K | $656.0K | $529.0K | $222.0K | $593.0K | |
| R&D Expense | $13M | $17M | $19M | $14M | $49M | $9M | $14M | $10M | $13M | $14M | $13M | $12M | $13M | $11M | $9M | $9M | |
| SG&A Expense | $5M | $6M | $6M | $5M | $6M | $13M | $11M | $7M | $8M | $11M | $10M | $11M | $12M | $11M | $11M | $10M | |
| Operating Expenses | $18M | $24M | $25M | $20M | $55M | $22M | $26M | $21M | $22M | $25M | $24M | $24M | $26M | $23M | $21M | $19M | |
| Operating Income | $-18M | $-24M | $-25M | $-20M | $-55M | $-15M | $-19M | $-13M | $-16M | $-20M | $-18M | $-18M | $-20M | $-17M | $-15M | $-15M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $58.0K | · | $58.0K | $58.0K | $58.0K | $56.0K | $58.0K | |
| Interest Income | $1M | $1M | $2M | $2M | $2M | $791.0K | $676.0K | $906.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $620.0K | |
| Other Non-op | $1M | $1M | $2M | $2M | $2M | $88M | $676.0K | $867.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $562.0K | |
| Pretax Income | $-17M | $-22M | · | · | $-53M | $73M | · | · | · | · | $-16M | $-16M | $-18M | · | $-14M | $-14M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-9.0K | $0 | |
| Net Income | $-17M | $-22M | $-23M | $-18M | $-53M | $73M | $-18M | $-13M | $-15M | $-18M | $-16M | $-16M | $-18M | $-15M | $-14M | $-14M | |
| EPS (Basic) | $-0.20 | $-0.32 | $-1.15 | $-0.26 | $-0.76 | $1.84 | $-0.68 | $-0.46 | $-0.54 | $-0.68 | $-0.60 | $-0.60 | $-0.67 | $-0.57 | $-0.48 | $-0.68 | |
| EPS (Diluted) | $-0.20 | $-0.32 | $-1.14 | $-0.26 | $-0.76 | $1.83 | $-0.68 | $-0.46 | $-0.54 | $-0.68 | $-0.60 | $-0.60 | $-0.67 | $-0.57 | $-0.48 | $-0.68 | |
| Shares (Basic) | 82,886,196 | 69,236,945 | · | 69,204,899 | 69,083,127 | 39,640,826 | · | 27,041,327 | 27,010,013 | 26,980,698 | · | 26,946,683 | 26,879,089 | 26,862,646 | · | 21,269,163 | |
| Shares (Diluted) | 82,886,196 | 69,236,945 | · | 69,204,899 | 69,083,127 | 39,932,539 | · | 27,041,327 | 27,010,013 | 26,980,698 | · | 26,946,683 | 26,879,089 | 26,862,646 | · | 21,269,163 | |
| EBITDA | $-18M | $-24M | · | $-20M | $-55M | $-15M | · | $-13M | $-16M | $-19M | · | $-18M | $-20M | $-17M | · | $-15M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $85M | $35M | $38M | $38M | $145M | $228M | $29M | $31M | $41M | $54M | $63M | $69M | $68M | $34M | $39M | $135M | |
| Short-term Investments | $105M | $88M | $108M | $125M | $32M | $3M | $19M | $32M | $37M | $34M | $46M | $51M | $67M | $117M | $134M | $48M | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $6M | $7M | $6M | $5M | $5M | $6M | $4M | $6M | $2M | $2M | |
| Inventory | · | · | $0 | $0 | $0 | $0 | $5M | $5M | $6M | $6M | $6M | $4M | $3M | $4M | $2M | $734.0K | |
| Prepaid Expense | $2M | $3M | $3M | $2M | $1M | $2M | $3M | $3M | $2M | $3M | $4M | $4M | $3M | $4M | $4M | $4M | |
| Current Assets | $192M | $126M | $149M | $165M | $179M | $233M | $61M | $77M | $93M | $103M | $125M | $133M | $145M | $165M | $180M | $190M | |
| PP&E (Net) | $1.0K | $2.0K | $3.0K | $4.0K | $9.0K | $25.0K | $7M | $6M | $6M | $6M | $5M | $4M | $3M | $2M | $508.0K | $457.0K | |
| PP&E (Gross) | $377.0K | $377.0K | $377.0K | $377.0K | $377.0K | $377.0K | $7M | $6M | $6M | $6M | $5M | $4M | $3M | $2M | $609.0K | · | |
| Accum. Depreciation | $376.0K | $375.0K | $374.0K | $373.0K | $368.0K | $352.0K | $463.0K | $416.0K | $369.0K | $320.0K | $270.0K | $226.0K | $183.0K | $140.0K | $101.0K | · | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-current Assets | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $194M | $127M | $151M | $167M | $181M | $234M | $70M | $86M | $102M | $111M | $132M | $140M | $151M | $171M | $184M | $194M | |
| Accounts Payable | $1M | $2M | $917.0K | $2M | $3M | $4M | $2M | $1M | $2M | $3M | $6M | $3M | $3M | $7M | $4M | $4M | |
| Accrued Liabilities | $10M | $9M | $14M | $8M | $5M | $9M | $15M | $14M | $14M | $11M | $14M | $12M | $10M | $11M | $15M | $14M | |
| Current Liabilities | $11M | $11M | $15M | $10M | $9M | $12M | $17M | $16M | $22M | $20M | $26M | $21M | $13M | $18M | $19M | $18M | |
| Capital Leases | · | · | $0 | $0 | $0 | $0 | $565.0K | $624.0K | $682.0K | $738.0K | $833.0K | $946.0K | $1M | $1M | $1M | $1M | |
| Other Non-current Liabilities | · | · | $0 | $0 | $0 | $0 | $202.0K | $393.0K | · | · | $0 | · | · | · | · | · | |
| Total Liabilities | $11M | $11M | $15M | $10M | $9M | $12M | $18M | $17M | $23M | $21M | $27M | $21M | $20M | $25M | $26M | $25M | |
| Common Stock | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | |
| Retained Earnings | $-392M | $-375M | $-353M | $-330M | $-312M | $-260M | $-333M | $-314M | $-302M | $-287M | $-269M | $-253M | $-236M | $-218M | $-203M | $-189M | |
| AOCI | $-63.0K | $-15.0K | $120.0K | $139.0K | $9.0K | $1.0K | $16.0K | $39.0K | $-27.0K | $-8.0K | $27.0K | $-16.0K | $-44.0K | $-32.0K | $-115.0K | $-99.0K | |
| Stockholders' Equity | $183M | $116M | $136M | $157M | $172M | $222M | $52M | $69M | $79M | $90M | $105M | $118M | $131M | $146M | $158M | $169M | |
| Liabilities + Equity | $194M | $127M | $151M | $167M | $181M | $234M | $70M | $86M | $102M | $111M | $132M | $140M | $151M | $171M | $184M | $194M | |
| Shares Outstanding | 57,009,010 | 47,196,564 | 47,145,719 | 47,128,362 | 47,128,362 | 46,784,618 | 24,680,708 | 24,614,834 | 24,614,834 | 24,554,205 | 24,554,205 | 24,525,860 | 24,519,860 | 24,436,990 | 24,435,007 | 24,395,117 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $50.0K | $44.0K | $44.0K | $43.0K | $38.0K | $46.0K | $12.0K | |
| Stock-based Comp | $2M | $2M | $2M | $3M | $3M | $2M | $2M | $3M | $3M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $-32.0K | $0 | |
| Restructuring | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $-15M | $-22M | $-17M | $-15M | $-53M | $-12M | $-15M | $-16M | $-9M | $-20M | $-10M | $-12M | $-17M | $-21M | $-11M | $-8M | |
| CapEx | $0 | $0 | $0 | $0 | $1.0K | $551.0K | $186.0K | $188.0K | $541.0K | $739.0K | $816.0K | $1M | $689.0K | $1M | $78.0K | $102.0K | |
| Investing Cash Flow | $-17M | $19M | $17M | $-92M | $-29M | $115M | $13M | $5M | $-4M | $11M | $4M | $13M | $51M | $16M | $-84M | $-48M | |
| Financing Cash Flow | $82M | $0 | $25.0K | $0 | $-850.0K | $95M | $53.0K | $0 | $87.0K | $-10.0K | $80.0K | $-75.0K | $313.0K | $8.0K | $-107.0K | $73M | |
| Net Change in Cash | $50M | $-3M | $-363.0K | $-107M | $-83M | $199M | $-2M | $-11M | $-13M | $-9M | $-6M | $641.0K | $34M | $-5M | $-96M | $16M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $0 | |
| Free Cash Flow | · | $-22M | · | · | · | $-12M | · | · | · | $-20M | · | · | · | $-23M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -213.0% | · | -186.0% | -252.2% | -364.5% | · | -299.5% | -315.1% | -286.8% | · | -354.2% | |
| Net Margin | · | · | · | · | · | 1021.9% | · | -174.0% | -236.0% | -341.7% | · | -273.6% | -289.8% | -259.5% | · | -341.0% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -273.6% | -289.8% | · | · | -341.0% | |
| EBITDA Margin | · | · | · | · | · | -213.0% | · | -186.0% | -252.2% | -363.6% | · | -299.5% | -315.1% | -286.1% | · | -354.2% | |
| ROA | -8.9% | -12.3% | · | -14.0% | -37.3% | 42.3% | · | -11.1% | -11.5% | -13.0% | · | -9.8% | -12.8% | -9.7% | · | -8.0% | |
| ROE | -9.4% | -13.1% | · | -15.7% | -41.9% | 46.8% | · | -13.4% | -13.9% | -15.5% | · | -11.3% | -15.0% | -11.2% | · | -9.0% | |
| ROIC | -9.9% | -20.2% | · | · | · | · | · | · | · | · | · | -15.1% | -14.9% | · | · | -8.9% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.4 | 11.4 | · | 16.8 | 20.4 | 19.0 | · | 4.9 | 4.2 | 5.2 | · | 6.5 | 11.2 | 9.3 | · | 10.6 | |
| Quick Ratio | 17.2 | 11.1 | · | 16.5 | 20.2 | 18.8 | · | 4.4 | 3.8 | 4.7 | · | 6.1 | 10.7 | 8.8 | · | 10.4 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -336.4 | · | -307.7 | -337.0 | -290.1 | · | -259.2 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | 0.0 | 0.0 | 0.3 | · | 0.2 | 0.2 | 0.1 | · | 0.3 | 0.3 | 0.3 | · | 1.6 | |
| Receivables Turnover | · | · | · | 0.0 | 0.0 | 2.9 | · | 1.2 | 1.3 | 1.0 | · | 1.5 | 2.2 | 1.4 | · | 3.7 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.21 | $2.46 | · | $3.33 | $3.65 | $4.74 | · | $2.80 | $3.20 | $3.68 | · | $4.82 | $5.36 | $5.97 | · | $6.93 | |
| Revenue / Share | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.18 | · | $0.27 | $0.23 | $0.20 | · | $0.22 | $0.23 | $0.22 | · | $0.20 | |
| Cash Flow / Share | · | $-0.32 | · | · | · | $-0.30 | · | · | · | $-0.73 | · | · | · | $-0.79 | · | · | |
| Cash / Share | $1.50 | $0.74 | · | $0.80 | $3.08 | $4.86 | · | $1.24 | $1.67 | $2.19 | · | $2.81 | $2.78 | $1.39 | · | $5.53 | |
| EPS (TTM) | $-1.92 | $-2.48 | · | $0.13 | $-0.07 | $0.15 | · | $-2.28 | $-2.42 | $-2.55 | · | $-2.32 | $-2.40 | $-2.60 | · | · |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $14M | $22M | $28M | · | $25M | $24M | $24M | · | $23M | $22M | $19M | · | $24M | |
| Net Income TTM | $-80M | $-116M | · | $-16M | $-10M | $28M | · | $-62M | $-65M | $-69M | · | $-63M | $-62M | $-62M | · | · | |
| Market Cap | $261M | $163M | · | $90M | $88M | $83M | · | $51M | $36M | $57M | · | $119M | $168M | $177M | · | $345M | |
| P/E | -2.4 | -1.4 | · | 14.6 | -26.7 | 11.9 | · | -0.9 | -0.6 | -0.9 | · | -2.1 | -2.9 | -2.8 | · | · | |
| P/S | · | · | · | 6.2 | 4.1 | 3.0 | · | 2.0 | 1.5 | 2.4 | · | 5.1 | 7.8 | 9.4 | · | 14.4 | |
| P/B | 1.4 | 1.4 | · | 0.6 | 0.5 | 0.4 | · | 0.7 | 0.5 | 0.6 | · | 1.0 | 1.3 | 1.2 | · | 2.0 | |
| P / Tangible Book | 1.4 | 1.4 | · | 0.6 | 0.5 | 0.4 | · | 0.7 | 0.5 | 0.6 | · | 1.0 | 1.3 | 1.2 | · | 2.0 | |
| P / Cash Flow | · | -7.3 | · | · | · | -7.0 | · | · | · | -2.9 | · | · | · | -8.3 | · | · | |
| Earnings Yield | -41.9% | -71.9% | · | 6.8% | -3.7% | 8.4% | · | -110.7% | -165.8% | -109.0% | · | -47.9% | -35.1% | -35.9% | · | · |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $7M | $26M | $24M | $15M | $14M |
| Betriebsgewinnmarge % | -1601.1% | -259.6% | -295.4% | -411.9% | -9930.1% |
| Nettoergebnis | $-21M | $-64M | $-66M | $-61M | $-110M |
| Verwässerte EPS | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 10.3 | 3.6 | 4.7 | 9.6 | 9.9 |
| Quick Ratio | 10.0 | 3.1 | 4.3 | 9.3 | 9.8 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-98M | $-61M | $-64M | $-50M | $-22M |
Institutionelle Eigentümer (13F) 82 Einreicher · $202.4M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
82
Gehaltener Wert
$202.4M
Neue Positionen
28
Geschlossene Positionen
11
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 28 (+6 vs. Vorquartal) | 11 (+7 vs. Vorquartal) | 30 (+15 vs. Vorquartal) | 10 (+2 vs. Vorquartal) | +9.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Yu Fan | $22.264.818 | 4.861.314 | 11,00% | Aktien |
| ACUTA CAPITAL PARTNERS, LLC | $21.461.477 | 4.685.912 | 10,60% | Aktien |
| QVT Financial LP | $21.139.947 | 4.615.709 | 10,44% | Aktien |
| MONTANOVA CAPITAL, LLC | $19.694.000 | 4.300.000 | 9,73% | Aktien |
| ORBIMED ADVISORS LLC | $18.019.076 | 3.934.296 | 8,90% | Aktien |
| Avoro Capital Advisors LLC | $13.050.261 | 2.849.402 | 6,45% | Aktien |
| Siren, L.L.C. | $10.703.927 | 2.337.102 | 5,29% | Aktien |
| KVP Capital Advisors, LP | $9.920.266 | 2.165.997 | 4,90% | Aktien |
| BlackRock, Inc. | $8.806.552 | 1.922.828 | 4,35% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.359.609 | 1.388.561 | 3,14% | Aktien |
| ADAR1 Capital Management, LLC | $6.143.585 | 1.341.394 | 3,04% | Aktien |
| ACORN CAPITAL ADVISORS, LLC | $5.218.283 | 1.139.363 | 2,58% | Aktien |
| STEMPOINT CAPITAL LP | $4.676.349 | 1.021.037 | 2,31% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $4.121.928 | 899.780 | 2,04% | Aktien |
| VANGUARD GROUP INC | $3.848.082 | 1.590.117 | 1,90% | Aktien |
| Ally Bridge Group (NY) LLC | $3.746.161 | 817.939 | 1,85% | Aktien |
| Woodline Partners LP | $1.999.692 | 436.614 | 0,99% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $1.895.305 | 413.822 | 0,94% | Aktien |
| STATE STREET CORP | $1.772.378 | 386.982 | 0,88% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $1.742.259 | 380.406 | 0,86% | Aktien |
| Eversept Partners, LP | $1.389.141 | 303.306 | 0,69% | Aktien |
| Verdad Advisers, LP | $1.380.792 | 301.483 | 0,68% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $1.358.483 | 296.612 | 0,67% | Aktien |
| AMES NATIONAL CORP | $1.333.269 | 4.571 | 0,66% | Aktien |
| Balyasny Asset Management L.P. | $1.319.576 | 288.117 | 0,65% | Aktien |
| NORTHERN TRUST CORP | $1.212.276 | 264.689 | 0,60% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $1.130.834 | 246.907 | 0,56% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.004.014 | 219.217 | 0,50% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $757.001 | 165.284 | 0,37% | Aktien |
| GOLDMAN SACHS GROUP INC | $580.552 | 126.758 | 0,29% | Aktien |
| Bank of New York Mellon Corp | $378.455 | 82.632 | 0,19% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $361.051 | 78.832 | 0,18% | Aktien |
| Point72 Asset Management, L.P. | $261.651 | 57.129 | 0,13% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $237.427 | 51.840 | 0,12% | Aktien |
| UBS Group AG | $232.851 | 50.841 | 0,12% | Aktien |
| Qube Research & Technologies Ltd | $224.388 | 48.993 | 0,11% | Aktien |
| Nuveen, LLC | $200.599 | 43.799 | 0,10% | Aktien |
| Jump Financial, LLC | $186.864 | 40.800 | 0,09% | Aktien |
| Invesco Ltd. | $179.440 | 39.179 | 0,09% | Aktien |
| BANK OF AMERICA CORP /DE/ | $158.587 | 34.626 | 0,08% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $153.064 | 33.420 | 0,08% | Aktien |
| DEUTSCHE BANK AG\ | $145.039 | 31.668 | 0,07% | Aktien |
| CITADEL ADVISORS LLC | $137.794 | 30.086 | 0,07% | Aktien |
| MORGAN STANLEY | $137.309 | 29.980 | 0,07% | Aktien |
| WELLS FARGO & COMPANY/MN | $124.457 | 27.174 | 0,06% | Aktien |
| RHUMBLINE ADVISERS | $112.338 | 24.529 | 0,06% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $111.583 | 24.363 | 0,06% | Aktien |
| TWO SIGMA ADVISERS, LP | $102.608 | 42.400 | 0,05% | Aktien |
| Vanguard Global Advisers, LLC | $89.205 | 19.477 | 0,04% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $85.646 | 18.700 | 0,04% | Aktien |
Aktivisten & 5%+-Eigentümer 13 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC, ANUPAM DALAL, Acuta Capital Fund, LP ×3 Einreichungen | 18. Mai 2026 | 9,00% | Änderung | Passive Anlage | SEC |
| Avoro Capital Advisors LLC, Avoro Ventures LLC, Behzad Aghazadeh ×6 Einreichungen | 14. Mai 2026 | 19,99% | Änderung | · | SEC |
| Neil Desai ×5 Einreichungen | 6. März 2025 | 4,90% | Änderung | · | SEC |
| BML Investment Partners, L.P., Leonard Braden Michael ×5 Einreichungen | 5. März 2025 | 4,98% | Änderung | Passive Anlage | SEC |
| Muneer A. Satter (2) ×5 Einreichungen | 12. November 2021 | · | Erste Einreichung | · | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP V LLC ×4 Einreichungen | 3. September 2021 | · | Erste Einreichung | · | SEC |
| Novartis Bioventures Ltd., Novartis AG ×7 Einreichungen | 15. Mai 2020 | · | Erste Einreichung | · | SEC |
| Kearny Venture Partners, L.P. (“KVP”), Kearny Venture Partners Entrepreneurs’ Fund, L.P. (“KVPE”), Kearny Venture Associates, L.L.C. (“KVA”), Caley Castelein (“Castelein”), Richard Spalding (“Spalding”), James Shapiro (“Shapiro”) ×2 Einreichungen | 4. Oktober 2018 | · | Erste Einreichung | · | SEC |
| Novartis Bioventures Ltd. (2), Novartis AG (2) | 27. März 2017 | · | Erste Einreichung | · | SEC |
| Venture Investors Early Stage Fund IV Limited Partnership (2), VIESF IV GP LLC (2) | 27. März 2017 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 4. April 2008 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 4. April 2008 | · | Erste Einreichung | · | SEC |
| Argyris Vassiliou | 4. April 2008 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 28 Insider · 12 Führungskräfte · 17 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| David James Lennon | CHIEF EXECUTIVE OFFICER | 15. September 2026 A | 569.643 | 0 | 6 | $-1.058.894 |
| Brendan Delaney | President and Chief Executive Officer | 1. März 2023 A | 20.000 | 0 | 0 | $0 |
| Stephen J Hoffman | Chief Executive Officer | 14. Mai 2019 A | 31.967 | 0 | 0 | $0 |
| Scott M. Giacobello | CHIEF FINANCIAL OFFICER | 15. September 2026 A | 333.489 | 0 | 3 | $-890.614 |
| Joseph H. Gardner | President | 16. März 2020 A | 453.019 | 0 | 0 | $0 |
| Margaret Dugan | Chief Medical Officer | 15. September 2026 A | 19.132 | 0 | 0 | $0 |
| David Dornan | Chief Scientific Officer | 15. September 2026 A | · | 0 | 0 | $0 |
| Bryan Ball | Chief Technical Operations Officer | 15. September 2026 A | 448.126 | 0 | 5 | $-635.055 |
| Lorettta M Itri | CHIEF MEDICAL OFFICER | 1. März 2024 A | · | 0 | 0 | $0 |
| Kevin G. Peters | Chief Scientific Officer and Acting Chief Medical Officer Exhibit 24: Power of Attorney | 16. März 2020 A | 320.536 | 0 | 0 | $0 |
| Michael W Rogers | Chief Financial and Chief Business Officer | 14. Mai 2019 A | · | 0 | 0 | $0 |
| Steve Pakola | Chief Medical Officer | 15. Februar 2019 A | · | 0 | 0 | $0 |
| Vijay K Iyengar | Direktor | 9. September 2026 A | · | 0 | 0 | $0 |
| Baiteng Zhao | Direktor | 12. Juni 2026 A | 1.250.000 | 0 | 0 | $0 |
| Neil Desai | Direktor | 12. Juni 2026 A | 1.211.543 | 0 | 0 | $0 |
| Emma Reeve | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Mohammad Hirmand | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Anupam Dalal | Direktor | 12. Juni 2026 A | 4.685.912 | 0 | 0 | $0 |
| Richard E Maroun | Direktor | 12. Juni 2026 A | · | 0 | 0 | $0 |
| Caley Castelein | Direktor | 12. Juni 2026 A | 274.796 | 0 | 0 | $0 |
| Karin M. Hehenberger | Direktor | 12. Juni 2024 A | · | 0 | 0 | $0 |
| Cheryl Cohen | Direktor | 17. Juni 2021 A | 8.020 | 0 | 0 | $0 |
| Chau Quang Khuong | Direktor | 18. Juni 2019 A | 5.193.946 | 0 | 0 | $0 |
| Satter Muneer A | Direktor | 18. Juni 2019 A | 5.621.835 | 0 | 0 | $0 |
| Paul M Weiss | Direktor | 15. März 2017 P | 1.576.167 | 0 | 0 | $0 |
| Dugel Pravin | · | 30. Juni 2021 A | 12.568 | 0 | 0 | $0 |
| Steven Prelack | · | 30. Juni 2021 A | 24.485 | 0 | 0 | $0 |
| Regina Marek | · | 16. März 2020 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 10 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 26.402 SH | 2. Oktober 2026 | Täglich |
| IWC · iShares Trust | 0,03% | 109.848 SH | 11. September 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 28.211 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,00% | 15.506 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,00% | 720.704 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 470.854 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 887.972 SH | 19. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 187.597 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.409 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 311.545 SH | 11. September 2026 | Täglich |
WHWK Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 14 Analysten
KAUF
Median-Ziel
$8.00
+116,2%
4 28,6%
Starker Kauf
6 42,9%
Kauf
4 28,6%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
7 Analysten · 2026-10-03Mittelwert-Ziel $7.71 +108,5%
← Unter allen Zielen
Aktueller Preis $3.70
Tief$4.00
Mittelwert$7.71
Hoch$10.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| WHWK | $114M | -7.3 | -72.5% | -288.3% | -13.4% | · |
| RNAC | $188M | -1.4 | -92.8% | -4658.6% | 202.4% | · |
| SION | $1.84B | -21.9 | · | · | -23.4% | · |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | · |
| ELDN | $114M | -2.9 | · | · | -69.4% | · |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | · |
| CUE | $29M | -1.1 | 195.8% | -96.9% | -119.3% | · |
| NKTX | $131M | -1.3 | · | · | -31.1% | · |
| CNTN | $112M | -2.7 | · | · | -18.0% | · |
| CHRS | $172M | 1.0 | 59.8% | 398.4% | 185.8% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026